YOUR CASELOAD CALCULATOR

Calculate how many patients are eligible for inclusion
in HOPE attend your clinic?

Breakthroughs that change patients’ lives®

  • Pfizer Saudi Limited

  • Al Riyadh - Al Aqeek Dis

  • King Abdullah Financial District, Building 4.07

  • Postal Code 13519

  • Tel: +966 12 2293500

  • Fax: +966 12 2293692

  • PP-LTV-SAU-0068

YOUR CASELOAD

How many patients are eligible for inclusion in HOPE attend your clinic?

NUMBER OF PATIENTS

*required

Please note: The data will not be stored or recorded, and will be used for this presentation only.

of your caseload, the HOPE data suggest that average of

Patients*

could have an improvement in their haemoglobin of >1 g/dL at week 721

*Number of patients is calculated based on 90% of the total number of patients
1. Howard, J., Ataga, K. I., Brown, R. C., Achebe, M., Nduba, V., El-Beshlawy, A., Hassab, H., Agodoa, I., Tonda, M., Gray, S., Lehrer-Graiwer, J., & Vichinsky, E. (2021). Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Haematology, (5)8, e323–e333.

of your caseload, the HOPE data suggest that average of

Patients#

could have an improvement in their haemoglobin of >2 g/dL at week 721

#Number of patients is calculated based on 59% of the total number of patients